Please use this identifier to cite or link to this item:
Title: Is there a role for proton pump inhibitor prophylaxis in haematology patients?
Austin Authors: Leitinger, Emma;Hui, Lisa ;Grigg, Andrew P 
Affiliation: Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria..
Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
University of Melbourne, Melbourne, Victoria, Australia
Issue Date: Jun-2019 2019-02-05
Publication information: Internal Medicine Journal 2019; 49(6): 694-701
Abstract: While proton pump inhibitors (PPIs) are widely prescribed as prophylaxis in selected haematology inpatient and outpatients , an informal survey of haematology units around Australia found wide variations in the specific indications for their use. This is consistent with a literature review which showed a paucity of robust evidence to support their use, specifically in chemotherapy-induced mucositis, thrombocytopenia or administration of high dose glucocorticosteroids in the absence of additional risk factors. Overuse is relevant both due to cost perspective emerging evidence of adverse events associated with prolonged PPI administration. A review of prescribing practices at our institution over a 14-month period found that approximately 60% of myeloma, lymphoma and autograft patients received PPI prophylaxis during and beyond chemotherapy without an accepted indication. We encourage institutions to review their PPI prescribing practices with the intent of rationalising their use, and to conduct studies aiming to fill the substantial gaps in our knowledge. This article is protected by copyright. All rights reserved.
DOI: 10.1111/imj.14241
PubMed URL: 30719802
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 25, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.